In Reply We appreciate the commentary by Wormald and Evans on our article.1 In this systematic review and meta-analysis of randomized clinical trials that enrolled patients with atrial fibrillation and venous thromboembolism, a 22% relative reduction in intraocular bleeding with novel anticoagulants compared with warfarin resulted in an absolute risk reduction of 0.8 bleeds per 1000 person-years.
Sun MT, Wong CX. Risk of Intraocular Bleeding and the New Anticoagulants: Not Such a Big Effect—Reply. JAMA Ophthalmol. 2017;135(11):1281–1282. doi:10.1001/jamaophthalmol.2017.4024
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.